UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin

Poupon, L; Lamoine, S; Pereira, V; Barriere, DA; Lolignier, S; Giraudet, F; Aissouni, Y; ... Busserolles, J; + view all (2018) Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology , 140 pp. 43-61. 10.1016/j.neuropharm.2018.07.026.

[img] Text
Poupon_Targeting_TREK-1_CombinedAAM.pdf - ["content_typename_Accepted version" not defined]
Access restricted to UCL open access staff until 27 July 2019.

Download (1MB)
[img] Text
Poupon_Targeting_TREK-1_Suppl.pdf - ["content_typename_Accepted version" not defined]
Access restricted to UCL open access staff until 27 July 2019.

Download (741kB)

Abstract

Neurotoxicity remains the most common adverse effect of oxaliplatin, limiting its clinical use. In the present study, we developed a mouse model of chronic oxaliplatin-induced neuropathy, which mimics both sensory and motor deficits observed in patients, in a clinically relevant time course. Repeated oxaliplatin administration in mice induced both cephalic and extracephalic long lasting mechanical and cold hypersensitivity after the first injection as well as delayed sensorimotor deficits and a depression-like phenotype. Using this model, we report that riluzole prevents both sensory and motor deficits induced by oxaliplatin as well as the depression-like phenotype induced by cumulative chemotherapeutic drug doses. All the beneficial effects are due to riluzole action on the TREK-1 potassium channel, which plays a central role in its therapeutic action. Riluzole has no negative effect on oxaliplatin antiproliferative capacity in human colorectal cancer cells and on its anticancer effect in a mouse model of colorectal cancer. Moreover, riluzole decreases human colorectal cancer cell line viability in vitro and inhibits polyp development in vivo. The present data in mice may support the need to clinically test riluzole in oxaliplatin-treated cancer patients and state for the important role of the TREK-1 channel in pain perception.

Type: Article
Title: Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin
Location: England
DOI: 10.1016/j.neuropharm.2018.07.026
Publisher version: https://doi.org/10.1016/j.neuropharm.2018.07.026
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Colorectal cancer, Neurotoxicity, Oxaliplatin, Prevention, Riluzole, TREK-1 potassium channel
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmacology
URI: http://discovery.ucl.ac.uk/id/eprint/10058455
Downloads since deposit
1Download
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item